MSD

News

ASH: MSD’s ROR1 drug hits the target in first-line lymphoma

The results of a phase 2 trial of MSD’s anti-ROR1 ADC zilovertamab vedotin back up the company's decision to start a phase 3 trial in DLBCL.

News

Kelun's MSD-partnered TROP2 drug gets first okay in China

Kelun-Biotech has become the second drugmaker to bring a TROP2 ADC to regulatory approval, after its sac-TMT drug was cleared in China

News

MSD adds rocket fuel to Winrevair's engine in PAH

ZENITH trial of MSD's Winrevair in PAH could add further momentum to an already impressive launch

News

MSD says subcutaneous Keytruda matches IV form

A subcutaneous formulation of MSD's top-selling cancer immunotherapy, Keytruda, was non-inferior to the current intravenous version in a head-to-head trial, setting up regulatory filings.

News

MSD joins PD-1/VEGF push in cancer with LaNova deal

There has been a lot of talk about drugs targeting both PD-1 and VEGF stealing the crown held by MSD's Keytruda in cancer immunotherapy.

News

BioNTech buys Biotheus and its Keytruda rival for $950m

BioNTech is clearly impressed with what it has seen with partner Biotheus' bispecific antibody for cancer, opting to buy the company outright to get full control of the drug.

ASH: MSD’s ROR1 drug hits the target in first-line lymphoma

Kelun's MSD-partnered TROP2 drug gets first okay in China

MSD adds rocket fuel to Winrevair's engine in PAH

MSD says subcutaneous Keytruda matches IV form

MSD joins PD-1/VEGF push in cancer with LaNova deal

BioNTech buys Biotheus and its Keytruda rival for $950m

Lilly bags FDA okay for Wegovy pill rival orforglipron

Using AI-driven synthetic personas to take your insights fur...

MSD

Editor's Picks